GENOME CAPITAL
We are company builders passionate about innovative HealthTech
About Us
Our team is a rare combination of technology entrepreneurs, prominent scientists and investment experts, who are also active leaders of the community of more than 3,000 founders of medtech projects from the BRICS markets who have raised more than 30 unicorns and hundreds of successful companies.
About Us
Our team is a rare combination of technology entrepreneurs, prominent scientists and investment experts, who are also active leaders of the community of more than 3,000 founders of medtech projects from the BRICS markets who have raised more than 30 unicorns and hundreds of successful companies.
Our Focus
We invest capital and expertise in talented teams and exciting science and technology.
We invest capital and expertise in talented teams and exciting science and technology.
Our focus
Healthcare costs continue to grow at a rapid pace. Genome Capital believes that now is the right time to invest in:
Healthcare costs continue to grow at a rapid pace. Genome Capital believes that now is the right time to invest in:
Robotic Medical devices
AI diagnostic
Telemedicine
NeuroTech
Bioimplants
-
Robotic Medical devices -
AI diagnostic -
Telemedicine -
NeuroTech -
Bioimplants
That can expand the foundations of medical practice, improve the quality of life and provide high returns for our investors.
That can expand the foundations of medical practice, improve the quality of life and provide high returns for our investors.
Impact
Impact
We believe that high financial and societal returns can coexist.
More than 5 bn people in emerging markets have limited access to medical services due to shortage of doctors in the region, lack of good infrastructure, and high cost of services and medicines.
New technologies in Life Science, IT and Robotics can change the rules of the game!
More than 5 bn people in emerging markets have limited access to medical services due to shortage of doctors in the region, lack of good infrastructure, and high cost of services and medicines.
New technologies in Life Science, IT and Robotics can change the rules of the game!
We believe that high financial and societal returns can coexist.
More than 5 bn people in emerging markets have limited access to medical services due to shortage of doctors in the region, lack of good infrastructure, and high cost of services and medicines.
New technologies in Life Science, IT and Robotics can change the rules of the game!
More than 5 bn people in emerging markets have limited access to medical services due to shortage of doctors in the region, lack of good infrastructure, and high cost of services and medicines.
New technologies in Life Science, IT and Robotics can change the rules of the game!
News
News
Send you project
Meet the Partners of GENOME CAPITAL
Send your project
Meet the Partners of GENOME CAPITAL.
Subscribe to the mailing list
Subscribe to the mailing list
